Scholarlink

Purpose <p>Radical surgery is the primary treatment for localized gastric cancer (GC), but the benefit of adjuvant chemotherapy in stage IB GC remains unclear. This study evaluates its impact on recurrence and survival post-gastrectomy.</p> Methods <p>We retrospectively analyzed 357 patients with pathological T1N1M0 or T2N0M0 GC who underwent radical gastrectomy (1994–2020). Clinicopathological data were collected, and propensity score matching (PSM) was used to minimize selection bias.</p> Results <p>The chemotherapy group was younger (<i>p</i> = 0.007), had lower Charlson comorbidity index scores (<i>p</i> = 0.006), more partial gastrectomies (<i>p</i> = 0.048), and higher lymphovascular invasion rates (<i>p</i> = 0.023). No significant differences were observed in disease-free (<i>p</i> = 0.346) or cancer-specific survival (<i>p</i> = 0.358) between groups, even after PSM.</p> Conclusions <p>Adjuvant chemotherapy did not improve survival. Large-scale randomized trials are needed to clarify its role in stage IB GC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Survival Impact of Adjuvant Chemotherapy on Stage IB Gastric Cancer Patients After Radical Surgery

  • 期刊论文

  • 发表日期：

    2026年4月18日

查看全文
  • Yi-Fu Chen,
  • Hao-Wei Kou,
  • Tsung-Hsing Chen,
  • Puo-Hsien Le,
  • Chia-Jung Kuo,
  • Shang-Yu Wang,
  • Wen-Chi Chou,
  • Ta-Sen Yeh,
  • Jun-Te Hsu

摘要

Purpose

Radical surgery is the primary treatment for localized gastric cancer (GC), but the benefit of adjuvant chemotherapy in stage IB GC remains unclear. This study evaluates its impact on recurrence and survival post-gastrectomy.

Methods

We retrospectively analyzed 357 patients with pathological T1N1M0 or T2N0M0 GC who underwent radical gastrectomy (1994–2020). Clinicopathological data were collected, and propensity score matching (PSM) was used to minimize selection bias.

Results

The chemotherapy group was younger (p = 0.007), had lower Charlson comorbidity index scores (p = 0.006), more partial gastrectomies (p = 0.048), and higher lymphovascular invasion rates (p = 0.023). No significant differences were observed in disease-free (p = 0.346) or cancer-specific survival (p = 0.358) between groups, even after PSM.

Conclusions

Adjuvant chemotherapy did not improve survival. Large-scale randomized trials are needed to clarify its role in stage IB GC.